查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1262028

發作性睡病市場-全球行業規模、份額、趨勢、機遇和預測，2018-2028 年，按類型、診斷、治療、最終用戶、地區和競爭進行分析

Narcolepsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Type, By Diagnosis, By Treatment, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在預測期內，全球發作性睡病市場預計將實現顯著增長。 這是由於該地區用於治療睡眠障礙的醫療保健行業的投資數量和規模不斷增加。 此外，由於壓力大的生活方式導致睡眠呼吸暫停和失眠等神經系統疾病的患病率增加，預計這些年來將推動市場增長。 同樣，根據臨床試驗，大公司正在投資開發低成本的發作性睡病治療方法，預計這將在預測期內進一步推動市場增長。 政府，針對發作性睡病藥物發現了 131 項試驗。 其中，發作性睡病類藥物可供18至55歲的男女服用。 此外，發作性睡病診斷技術的顯著改進以及製藥公司開發具有長期益處和減少副作用的變體將進一步增加對發作性睡病的需求，推動市場增長到 2028 年。預計。 此外，越來越多的市場參與者專注於為用戶的利益開發新藥和治療方法，預計也將增加對發作性睡病的需求並支持市場的增長。 根據疾病預防控制中心的數據，到 2020 年，34.8% 的美國人口將患有發作性睡病或睡眠障礙。

發作性睡病患病率上升

我們預測，壓力大的生活方式、遺傳缺陷、青春期和更年期期間發生的荷爾蒙變化以及睡眠模式的劇烈變化將增加發作性睡病的嚴重程度和患病率。它一直是推動這一時期市場增長的主要因素。 此外，發作性睡病藥物還可用於治療睡眠呼吸暫停、失眠和不寧腿綜合徵，進一步推動市場增長。 發作性睡病患病率上升和肥胖人口增加是整個預測期內發作性睡病市場增長的主要驅動力。 莫達非尼在患者治療中的使用也刺激了市場擴張，因為它的副作用比其他興奮劑少。 因此，適當的治療將有助於預防此類疾病，這有望推動全球發作性睡病市場。 據估計，有 1-4% 的兒童患有睡眠呼吸暫停症，其中大多數年齡在 2-8 歲之間。

增加特定機構的舉措

在預測期內，人們對發作性睡病治療的認識不斷提高，預計將產生顯著增長。 此外，莫達非尼用於治療副作用較少的患者，有助於預防此類疾病，在預測期內引領發作性睡病市場。 印度和南非等國家的政府機構正在開展運動，向人們和醫護人員宣傳嗜睡症藥物和嗜睡症治療的好處，不僅在發展中地區，而且在農村地區，這將在預測期內促進市場增長. 預計。 根據 2021 年 11 月更新的國家神經疾病和中風研究所情況說明書，發作性睡病影響了美國 135,000 至 200,000 人。 多年來，預計美國對發作性睡病藥物開發的資金增加將進一步推動市場增長。 此外，在預測期內，快速採用嗜睡症藥物的新療法有望推動市場增長。 此外，美國非營利組織 Project Sleep 發起了一個名為“發作性睡病的崛起之聲”的計劃，向當地社區發送文本和聲音，以提高認識並減少對其他患有發作性睡病的人的社會恥辱感。我們鼓勵他們分享他們的故事通過與他們交談。

近期發展

  • 2021 年 12 月，Rygand Pharmaceuticals, Inc. 宣布擴大其子公司 Icagen 和 GSK 之間的現有合作和許可協議。底部。 此次擴張將利用 Icagen 基於離子通道的發現技術和針對跨膜蛋白的小分子療法的獨特專業知識。 這項新協議建立在 2020 年 12 月的初步協議基礎上，旨在識別和開發與神經系統疾病相關的特定基因驗證分子靶標的抑製劑。
  • 2020 年 1 月 Adair Pharmaceuticals, Inc. 和 NLS Pharmaceuticals Limited 宣布 Mazindol CR 候選產品用於治療發作性睡病和注意力缺陷多動障礙 (ADHD)，同意共同開發

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 完成臨床試驗
  • 已完成臨床試驗
  • 管道細分（按開發階段）
  • 管道細分（按狀態
  • 管道細分（按研究類型）
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第 6 章嗜睡症全球市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（類型 1、類型 2、其他）
    • 通過診斷（多導睡眠圖、多次睡眠潛伏期測試等）
    • 通過治療藥物（興奮劑、抗抑鬱藥、羥丁酸鈉等）
    • 最終用戶（醫院、診所、零售藥店等）
    • 按公司分類（2022 年）
  • 產品地圖
    • 按類型
    • 通過診斷
    • 通過治療
    • 最終用戶

第 7 章北美髮作性睡病市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（類型 1、類型 2、其他）
    • 通過診斷（多導睡眠圖、多次睡眠潛伏期測試等）
    • 通過治療藥物（興奮劑、抗抑鬱藥、羥丁酸鈉等）
    • 最終用戶（醫院、診所、零售藥店等）
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章歐洲發作性睡病市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（類型 1、類型 2、其他）
    • 通過診斷（多導睡眠圖、多次睡眠潛伏期測試等）
    • 通過治療藥物（興奮劑、抗抑鬱藥、羥丁酸鈉等）
    • 最終用戶（醫院、診所、零售藥店等）
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第 9 章亞太嗜睡症市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（類型 1、類型 2、其他）
    • 通過診斷（多導睡眠圖、多次睡眠潛伏期測試等）
    • 通過治療藥物（興奮劑、抗抑鬱藥、羥丁酸鈉等）
    • 最終用戶（醫院、診所、零售藥店等）
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 10 章南美髮作性睡病市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（類型 1、類型 2、其他）
    • 通過診斷（多導睡眠圖、多次睡眠潛伏期測試等）
    • 通過治療藥物（興奮劑、抗抑鬱藥、羥丁酸鈉等）
    • 最終用戶（醫院、診所、零售藥店等）
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲發作性睡病市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（類型 1、類型 2、其他）
    • 通過診斷（多導睡眠圖、多次睡眠潛伏期測試等）
    • 通過治療藥物（興奮劑、抗抑鬱藥、羥丁酸鈉等）
    • 最終用戶（醫院、診所、零售藥店等）
    • 按國家
  • MEA：國家分析
    • 南非發作性睡病
    • 沙特阿拉伯發作性睡病
    • 阿聯酋發作性睡病

第 12 章市場動態

  • 司機
    • 發作性睡病的患病率越來越高
    • 政府機構加大力度
  • 做
    • 關於發作性睡病藥物的副作用
    • 與發作性睡病藥物相關的誤診

第13章市場趨勢與發展

  • 近期發展狀況
  • 併購
  • 產品發布

第 14 章全球嗜睡症市場：SWOT 分析

第 15 章波特的五力分析

  • 行業競爭
  • 新進入的可能性
  • 供應商的力量
  • 客戶力量
  • 替代品的威脅

第十六章競爭格局關於

  • 業務概覽
  • 提供的產品
  • 近期發展狀況
  • 財務（據報導）
  • 主要人物
  • SWOT 分析
    • Jazz Pharmaceuticals Plc.
    • BIOPROJET.
    • Arena Pharmaceuticals, Inc.
    • Graymark Healthcare, Inc.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG.
    • Shire.
    • Shionogi Inc.
    • Ligand Pharmaceuticals, Inc.

第 17 章戰略建議

簡介目錄
Product Code: 14688

The global narcolepsy market is anticipated to register an impressive growth rate during the forecast period. This can be ascribed to the rising number and size of investments in the healthcare sector for the treatment of sleep disorders across the region. Additionally, the growing prevalence of neurological disorders such as sleep apnea and insomnia due to stressful lifestyles is expected to drive the growth of the market over the years. Similarly, the major players are investing in the development of narcolepsy drugs at low cost, which is expected to further drive the growth of the market over the forecast period, according to Clinical trials. Gov,131 studies have been found for narcolepsy drugs. Among them, narcolepsy cataplexy-type drugs can be taken by both males and females between 18-55 years of age. Moreover, significant improvements in the diagnostic technologies for narcolepsy and pharmaceutical companies are developing variants with long-term benefits and reduced side which are further expected to increase the demand for narcolepsy, thereby fuelling the market growth through 2028. Furthermore, an increasing number of major players in the market focusing on developing new drugs and therapies for the benefit of users is further expected to increase the demand for narcolepsy, thereby supporting the market growth. According to CDC, in 2020, 34.8 % of people were affected with narcolepsy or sleep disorder among the U.S population.

Growing Prevalence of Narcolepsy

The growing severity of the disease and the growing number of people affected by narcolepsy due to stressful lifestyles, an inherited genetic fault, hormonal changes that take place during puberty or menopause, and a sudden change in sleep patterns are the main factors driving the growth of the market during the forecast period. Moreover, narcolepsy medications can also be used to treat sleep apnea, insomnia, and restless legs syndrome, which will further drive the growth of the market. The major drivers of the narcolepsy market growth throughout the forecast period are rising narcolepsy prevalence and a growing obese population. In addition, because it has fewer adverse effects than other stimulants, the use of modafinil to treat patients is adding to its market expansion. So, proper treatment can aid in the prevention of such ailments, which is expected to drive the global narcolepsy market. It's estimated that 1 to 4% of children suffer from sleep apnea, many of them being between 2 and 8 years old.

Growing Initiatives by Government Organizations

Growing awareness about narcolepsy treatment among the population is expected to create significant growth during the forecast period. Moreover, the use of modafinil to treat patients because it has fewer side effects, and it can help to prevent such disorders, thereby driving the narcolepsy market during the forecast period. Government organizations from different countries, such as India and South Africa, have taken initiatives for campaigns to educate people and health workers about the narcolepsy drug's advantages and narcolepsy treatment in developing as well as rural areas, which is expected to boost market growth during the forecast period. According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. The rise in donations for the development of narcolepsy treatments in the United States is further anticipated to drive the growth of the market over the years. Moreover, the rapid adoption of a new therapy for the treatment of narcolepsy drugs is anticipated to drive market growth over the forecast period. Furthermore, Project Sleep, a non-profit organization based in the United States, launched a program called "Rising Voices of Narcolepsy" to educate people about narcolepsy to share their stories through writing and verbally addressing local communities to raise awareness and reduce social stigma among others suffering from the disease.

Market Segmentation

The global narcolepsy market can be segmented on the basis of type, diagnosis, treatment, end user, and by region. Based on the type, the market can be segmented into Type 1, Type 2, and Others. Based on the diagnosis, the market can be further divided into polysomnograms, multiple sleep latency tests, and others. On the basis of the treatment, the market can be further split into stimulants, antidepressants, sodium oxybate, and others. Based on end users, the market can be split into hospitals, clinics, retail pharmacies, and others. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global narcolepsy market on account of the increasing incidence of sleep disorders in the country.

Recent Developments

  • In December 2021, Ligand Pharmaceuticals, Inc. announced the expansion of its existing collaboration and license agreement between its subsidiary, Icagen, and GSK. This expansion will leverage Icagen's ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
  • In January 2020, Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. collaborated to develop mazindol CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).

Market Players

Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc are some of the leading players operating in the Global Narcolepsy Market.

Report Scope

In this report, the global narcolepsy market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Narcolepsy Market, By Type:

  • Type 1
  • Type 2
  • Others

Narcolepsy Market, By Diagnosis:

  • Polysomnogram
  • Multiple Sleep Latency Test
  • Others

Narcolepsy Market, By Treatment:

  • Stimulants
  • Antidepressants
  • Sodium Oxybate
  • Others

Narcolepsy Market, By Route of End User:

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Others

Narcolepsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Narcolepsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Type 1, Type 2, Others)
    • 6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
    • 6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
    • 6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
    • 6.2.5. By Company (2022)
  • 6.3. Product Map
    • 6.3.1 By Type
    • 6.3.2 By Diagnosis
    • 6.3.3 By Treatment
    • 6.3.4 By End User

7. North America Narcolepsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Type 1, Type 2, Others)
    • 7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
    • 7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
    • 7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Narcolepsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnosis
        • 7.3.1.2.3. By Treatment
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Narcolepsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnosis
        • 7.3.2.2.3. By Treatment
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Narcolepsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnosis
        • 7.3.3.2.3. By Treatment
        • 7.3.3.2.4. By End User

8. Europe Narcolepsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Type 1, Type 2, Others)
    • 8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
    • 8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
    • 8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Narcolepsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnosis
        • 8.3.1.2.3. By Treatment
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Narcolepsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnosis
        • 8.3.2.2.3. By Treatment
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Narcolepsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnosis
        • 8.3.3.2.3. By Treatment
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Narcolepsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnosis
        • 8.3.4.2.3. By Treatment
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Narcolepsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnosis
        • 8.3.5.2.3. By Treatment
        • 8.3.5.2.4. By End User

9. Asia-Pacific Narcolepsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Type 1, Type 2, Others)
    • 9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
    • 9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
    • 9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Narcolepsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnosis
        • 9.3.1.2.3. By Treatment
        • 9.3.1.2.4. By End User
    • 9.3.2. India Narcolepsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnosis
        • 9.3.2.2.3. By Treatment
        • 9.3.2.2.4. By End User
    • 9.3.3. Japan Narcolepsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnosis
        • 9.3.3.2.3. By Treatment
        • 9.3.3.2.4. By End User
    • 9.3.4. South Korea Narcolepsy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Diagnosis
        • 9.3.4.2.3. By Treatment
        • 9.3.4.2.4. By End User
    • 9.3.5. Australia Narcolepsy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Diagnosis
        • 9.3.5.2.3. By Treatment
        • 9.3.5.2.4. By End User

10. South America Narcolepsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Type 1, Type 2, Others)
    • 10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
    • 10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
    • 10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Narcolepsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnosis
        • 10.3.1.2.3. By Treatment
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Narcolepsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnosis
        • 10.3.2.2.3. By Treatment
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Narcolepsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnosis
        • 10.3.3.2.3. By Treatment
        • 10.3.3.2.4. By End User

11. Middle East and Africa Narcolepsy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Type 1, Type 2, Others)
    • 11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
    • 11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
    • 11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Narcolepsy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Diagnosis
        • 11.3.1.2.3. By Treatment
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Narcolepsy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Diagnosis
        • 11.3.2.2.3. By Treatment
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Narcolepsy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Diagnosis
        • 11.3.3.2.3. By Treatment
        • 11.3.3.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
    • 12.1.1 Increase in Prevalence of Narcolepsy
    • 12.1.2 Growing Initiatives by Government Organizations
  • 12.2. Challenges
    • 12.2.1 Adverse effect related to narcolepsy drugs.
    • 12.2.2 Misdiagnosis related to narcolepsy treatment

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Narcolepsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
    • 16.6.1 Jazz Pharmaceuticals Plc.
    • 16.6.2 BIOPROJET.
    • 16.6.3 Arena Pharmaceuticals, Inc.
    • 16.6.4 Graymark Healthcare, Inc.
    • 16.6.5 Mylan N.V.
    • 16.6.6 Teva Pharmaceutical Industries Ltd.
    • 16.6.7 Novartis AG.
    • 16.6.8 Shire.
    • 16.6.9 Shionogi Inc.
    • 16.6.10 Ligand Pharmaceuticals, Inc.

17. Strategic Recommendations